TRTMNT W/LAMIVUDINE+STAVUDINE+ABACAVIR+AMPRENAVIR/RITONAVIR W/SUPV INTERRUPTION

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。这项研究的目的是看看是否使用五个抗？在HIV感染的早期阶段，HIV药物可以使血液和某些身体组织中的HIV病毒无法检测到，以及即使在停止服用这些药物后，病毒是否仍然无法检测到。 本研究将使用拉米夫定（3 TC，Epivir）、司他夫定（d4 T，Zerit）、阿巴卡韦（ABC，1592 U89，Ziagen）、利托那韦（RTV，Norvir）和安普那韦（APV，141 W 94，Agenerase）。也可以使用去羟肌苷（ddI，Videx <$）和奈非那韦（NFV，Viracept <$）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to see if using a combination of five anti?HIV drugs during the early stage of HIV infection can make the HIV virus in the blood and in certain body tissues undetectable, and whether the virus will stay undetectable even after you stop taking these drugs. This study will use lamivudine (3TC, Epivir¿), stavudine (d4T, Zerit¿), abacavir (ABC, 1592U89, Ziagen¿), ritonavir (RTV, Norvir¿), and amprenavir (APV, 141W94, Agenerase¿). Didanosine (ddI, Videx¿) and nelfinavir (NFV, Viracept¿) may also be used.